SAMHSA released a formal 2026 advisory instructing primary care physicians to evaluate cannabis use based on clinical signs of harm, not simply patient use. Dr. Caplan breaks down what this federal guidance actually says, where current diagnostic tools still fall short, and what patients using medical cannabis should know to protect themselves in clinical settings.
New Trial: 1:1 THC:CBD Oil Reduces Fibromyalgia Pain and Improves Sleep
A new double-blind, placebo-controlled trial found that cannabis oil with equal amounts of THC and CBD meaningfully reduced pain and improved sleep in fibromyalgia patients. The trial, conducted across three Australian research institutions, achieved a 92% completion rate with no serious adverse events. Dr. Benjamin Caplan of CED Clinic reviews what the findings mean for patients considering cannabis oil fibromyalgia pain management.
A Synthetic Cannabinoid Did NOT Reduce Opioid Use After Knee Replacement Surgery
A new postoperative randomized trial found no significant opioid reduction from a synthetic cannabinoid after total knee arthroplasty. The findings challenge broad assumptions that cannabinoids reliably reduce opioid use in every pain setting. The study adds important nuance to the cannabinoid pain conversation.
What the Latest Physiology Research Reveals About Cannabis Formulation and Diabetes Risk
A Journal of Physiology study from UC Riverside found that whole cannabis extract reversed the fat-to-pancreas signaling failure behind type 2 diabetes—while purified THC alone did not. The findings suggest the entourage effect may have direct implications at the level of metabolic disease biology, not just symptom management. Dr. Caplan offers clinical perspective on what this means for patients interested in cannabis extract metabolic health applications.
The Endocannabinoid System and Myelin Regeneration: A Clinical Breakdown
A new preclinical study from Complutense University has found that CB1 receptor myelin repair mechanisms depend on intact endocannabinoid signaling at a critical cellular window. Researchers removed CB1 receptors specifically from newly formed oligodendrocytes in mice and observed that remyelination failed, neuroinflammation worsened, and motor recovery did not occur. While the findings are in animals and no cannabinoid was tested, they establish a specific mechanistic role for the endocannabinoid system in the brain’s ability to repair itself after injury.
What UK Biobank Data Suggests About Cannabis, BMI, Diabetes, and Hypertension
This cannabis metabolic health study analyzed 91,002 UK Biobank participants to explore links between cannabis use, diabetes, hypertension, and obesity risk. Researchers found lower rates of several metabolic conditions among cannabis users, but BMI substantially altered the associations. The findings support a more individualized, endocannabinoid-informed approach to metabolic counseling while reinforcing the limits of observational data.
A clinician-led analysis of causation, confounding, and mental health risk interpretation
This cannabis psychosis risk review examines how the 2026 JAMA Internal Medicine paper interprets observational mental health data. The analysis explores confounding, reverse causation, exposure definition problems, and the difference between relative and absolute risk. It also explains what cautious clinicians can responsibly conclude about cannabis, psychosis risk, bipolar disorder, anxiety, and adolescent exposure.
How CBD Interfered With HIV Entry Across Multiple Immune Cells
CBD HIV transmission prevention research published in Mucosal Immunology found that cannabidiol disrupted HIV-1 infection across multiple immune cell populations in laboratory and human tissue models. Researchers at Institut Cochin identified a TRPV1-CGRP signaling mechanism that appeared to suppress viral transmission at mucosal entry points. Dr. Caplan explains what the study actually showed, what remains unknown, and why this finding is biologically important without yet changing clinical practice.
What the 2026 DOJ Rescheduling Order Means in Practice
On April 23, 2026, the U.S. DOJ moved state-licensed medical cannabis to Schedule III, the first federal acknowledgment of accepted medical value in 55 years. Dr. Caplan breaks down what actually changed for patients, physicians, and the research pipeline.